Skip to content

Arrowhead Research ARWR Enterprise value

Enterprise value at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$12.92B+175%
ALN
Alnylam PharmaceuticalsALNY
$42.43B+24.1%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$16.77B+178%
Madrigal Pharmaceuticals, Inc. logo
Madrigal Pharmaceuticals, Inc.MDGL
$12.15B+67.5%
Royalty Pharma logo
Royalty PharmaRPRX
$28.94B+44.6%
AbbVie logo
AbbVieABBV
$460.96B+24.7%

Other financials

Income statement

See full
Revenue$73.7M-86.4%
Operating income-$141.3M-137%
Net income-$132.7M-136%
EPS (diluted)-$0.93-134%

Balance sheet

See full
Cash & equivalents$188.5M+1.5%
Total debt$107.9M-5.6%
Total equity$614.0M-10.1%
Total assets$2.3B+44.2%

Cash flow

See full
Operating cash flow$84.4M-81.6%
CapEx$2.6M-51.6%
Free cash flow$81.9M-82.0%

Valuation

See full
Market cap$11.52B+402%
P/S18.5×+14.3×

Profitability

See full
Operating margin-35.7%+63.6pp
Net margin-48.4%+240pp
FCF margin1.8%+0.9pp

Returns & leverage

See full
Return on equity-46.4%+341pp
Debt / equity0.2×0.0×
Current ratio6.2×+1.1×

Where this comes from

Calculated from Arrowhead Research’s reported figures.

The official record: Arrowhead Research’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arrowhead Research's enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arrowhead Research's enterprise value?
Arrowhead Research (ARWR) reported enterprise value of $8.7B in Q1 2026.
How has Arrowhead Research's enterprise value changed year-over-year?
Arrowhead Research's enterprise value increased by 418.4% year-over-year, from $1.68B to $8.7B.
What is the long-term trend for Arrowhead Research's enterprise value?
Over 5 years (2020 to 2025), Arrowhead Research's enterprise value has grown at a 1.2% compound annual growth rate (CAGR), from $4.38B to $4.65B.
What does enterprise value mean?
What it would cost to buy the entire business, debt included and cash netted out.
How do you interpret enterprise value?
The capital-structure-neutral valuation base — used in EV/EBITDA and EV/Sales to compare companies with different leverage on a like-for-like footing.
How does enterprise value compare across companies?
Comparable across non-financial companies via the EV multiples it feeds; not used for banks and insurers.